Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Pharmacy staff profile

Associate Professor Bruce Russell

PositionAssociate Professor in Clinical Pharmacy
QualificationsBPharm(Hons) PhD
Research summaryBiomarkers that enable the prediction of a response to treatment for severe mental health disorders
TeachingI coordinate and teach into the postgraduate paper, Pharmacy 523 and teach clinical pharmacy to third and fourth year students
Memberships
  • Member of the Schizophrenia International Research Society (SIRS)
  • Member of the College of Problems on Drug Dependence, USA
  • Member of the Pharmaceutical Society of New Zealand
ClinicalThe majority of my research is with patients so I regularly engage with service user groups and enjoy talking to carers and clinical staff whenever possible.

Research

My research focuses on investigating the psychopharmacology and underlying pathophysiology of the severe mental illnesses such as schizophrenia with an emphasis on treatment-resistance. I aim to discover biomarkers that will enable the prediction of an individual's response to drug treatment. I also have an active interest in the psychopharmacology of both new and 'old' recreationally used drugs and the mechanisms underlying drug addiction.

Associate Professor Bruce Russell on Google Scholar

Publications

McNabb, C. B., Tait, R. J., McIlwain, M. E., Anderson, V. M., Suckling, J., Kydd, R. R., & Russell, B. R. (2017). Functional network dysconnectivity as a biomarker of treatment resistance in schizophrenia. Schizophrenia Research. Advance online publication. doi: 10.1016/j.schres.2017.10.015

McIntosh, H. D., Russell, B. R., Cochran, J. R., & Sollers, III, J. J. (2017). The heart of the pressor effect: Acute caffeine ingestion and resting heart rate variability. Journal of Caffeine Research, 7(1), 23-30. doi: 10.1089/jcr.2016.0003

Ram, S., Hussainy, S., Henning, M., Stewart, K., Jensen, M., & Russell, B. (2017). Attitudes toward cognitive enhancer use among New Zealand tertiary students. Substance Use & Misuse, 52(11), 1387-1392. doi: 10.1080/10826084.2017.1281313

McGregor, A. L., Dysart, J., Tingle, M. D., Russell, B. R., Kydd, R. R., & Finucane, G. (2016). Varenicline improves motor and cognitive symptoms in early Huntington’s disease. Neuropsychiatric Disease & Treatment, 12, 2381-2386. doi: 10.2147/NDT.S111083

Lee, H., Wang, G. Y., Curley, L. E., Kydd, R. R., Kirk, I. J., & Russell, B. R. (2016). Investigation of the effects of 'piperazine-containing party pills' and dexamphetamine on interhemispheric communication using electroencephalography. Psychopharmacology, 233(15), 2869-2877. doi: 10.1007/s00213-016-4335-5

Chapter in Book - Research

Dalley, J. W., & Russell, B. (2014). Molecular imaging studies in stimulant addiction: A cross-species perspective. In R. A. J. O. Dierckx, A. Otte, E. F. J. de Vries, A. van Waarde & J. A. den Boer (Eds.), PET and SPECT in psychiatry. (pp. 515-534). Berlin, Germany: Springer. doi: 10.1007/978-3-642-40384-2_22

Lin, J. C., & Russell, B. R. (2012). Stimulants: Neuroimaging and treatments. In J. J. Canales (Ed.), Emerging targets for drug addiction treatment. (pp. 17-62). Nova Science.

^ Top of page

Journal - Research Article

McNabb, C. B., Tait, R. J., McIlwain, M. E., Anderson, V. M., Suckling, J., Kydd, R. R., & Russell, B. R. (2017). Functional network dysconnectivity as a biomarker of treatment resistance in schizophrenia. Schizophrenia Research. Advance online publication. doi: 10.1016/j.schres.2017.10.015

Ram, S., Hussainy, S., Henning, M., Stewart, K., Jensen, M., & Russell, B. (2017). Attitudes toward cognitive enhancer use among New Zealand tertiary students. Substance Use & Misuse, 52(11), 1387-1392. doi: 10.1080/10826084.2017.1281313

McIntosh, H. D., Russell, B. R., Cochran, J. R., & Sollers, III, J. J. (2017). The heart of the pressor effect: Acute caffeine ingestion and resting heart rate variability. Journal of Caffeine Research, 7(1), 23-30. doi: 10.1089/jcr.2016.0003

McGregor, A. L., Dysart, J., Tingle, M. D., Russell, B. R., Kydd, R. R., & Finucane, G. (2016). Varenicline improves motor and cognitive symptoms in early Huntington’s disease. Neuropsychiatric Disease & Treatment, 12, 2381-2386. doi: 10.2147/NDT.S111083

Lee, H., Wang, G. Y., Curley, L. E., Kydd, R. R., Kirk, I. J., & Russell, B. R. (2016). Investigation of the effects of 'piperazine-containing party pills' and dexamphetamine on interhemispheric communication using electroencephalography. Psychopharmacology, 233(15), 2869-2877. doi: 10.1007/s00213-016-4335-5

Lagas, A. K., Black, J. M., Byblow, W. D., Fleming, M. K., Goodman, L. K., Kydd, R. R., Russell, B. R., … Thompson, B. (2016). Fluoxetine does not enhance visual perceptual learning and triazolam specifically impairs learning transfer. Frontiers in Human Neuroscience, 10, 532. doi: 10.3389/fnhum.2016.00532

Curley, L. E., Kydd, R. R., Kirk, I. J., & Russell, B. R. (2016). Using fMRI to compare the effects of benzylpiperazine with dexamphetamine: Their differences during the Stroop paradigm. Journal of Integrative Neuroscience, 15, 109. doi: 10.1142/S0219635216500084

Doborjeh, M. G., Wang, G. Y., Kasabov, N. K., Kydd, R., & Russell, B. (2016). A spiking neural network methodology and system for learning and comparative analysis of EEG data from healthy versus addiction treated versus addiction not treated subjects. IEEE Transactions on Biomedical Engineering, 63(9), 1830-1841. doi: 10.1109/TBME.2015.2503400

Lee, H., Wang, G. Y., Curley, L. E., Sollers, J. J., Kydd, R. R., Kirk, I. J., & Russell, B. R. (2016). Acute effects of BZP, TFMPP and the combination of BZP and TFMPP in comparison to dexamphetamine on an auditory oddball task using electroencephalography: A single-dose study. Psychopharmacology, 233(5), 863-871. doi: 10.1007/s00213-015-4165-x

Wang, G. Y., Kydd, R. R., & Russell, B. R. (2016). Quantitative EEG and low-resolution electromagnetic tomography (LORETA) imaging of patients undergoing methadone treatment for opiate addiction. Clinical EEG & Neuroscience, 47(3), 180-187. doi: 10.1177/1550059415586705

Ram, S., Hussainy, S., Henning, M., Jensen, M., & Russell, B. (2016). Prevalence of cognitive enhancer use among New Zealand tertiary students. Drug & Alcohol Review, 35(3), 345-351. doi: 10.1111/dar.12294

Turner, C. E., Russell, B. R., & Gant, N. (2015). Comparative quantification of dietary supplemented neural creatine concentrations with 1H-MRS peak fitting and basis spectrum methods. Magnetic Resonance Imaging, 33(9), 1163-1167. doi: 10.1016/j.mri.2015.06.018

Anderson, V. M., McIlwain, M. E., Kydd, R. R., & Russell, B. R. (2015). Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders? Psychiatry Research, 230(3), 811-818. doi: 10.1016/j.psychres.2015.10.036

Curley, L. E., Kydd, R. R., Robertson, M. C., Pillai, A., McNair, N., Lee, H., … Russell, B. R. (2015). Acute effects of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) using functional magnetic resonance imaging (fMRI) and the Stroop task: A pilot study. Psychopharmacology, 232(16), 2969-2980. doi: 10.1007/s00213-015-3933-y

Wang, G. Y., Kydd, R., & Russell, B. R. (2015). Resting EEG and ERPs findings in methadone-substituted opiate users: A review. Acta Neurologica Belgica, 115(4), 539-546. doi: 10.1007/s13760-015-0476-2

Goldstein, M. E., Anderson, V. M., Pillai, A., Kydd, R. R., & Russell, B. R. (2015). Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. International Journal of Neuropsychopharmacology, 18(6), pyu117. doi: 10.1093/ijnp/pyu117

Lin, J. C., Jan, R. K., Kydd, R. R., & Russell, B. R. (2015). Investigating the microstructural and neurochemical environment within the basal ganglia of current methamphetamine abusers. Drug & Alcohol Dependence, 149, 122-127. doi: 10.1016/j.drugalcdep.2015.01.026

Anderson, V. M., Goldstein, M. E., Kydd, R. R., & Russell, B. R. (2015). Extensive gray matter volume reduction in treatment-resistant schizophrenia. International Journal of Neuropsychopharmacology, 18(7), pyv016. doi: 10.1093/ijnp/pyv016

Wang, G. Y., Kydd, R., & Russell, B. R. (2015). Auditory event-related potentials in methadone substituted opiate users. Journal of Psychopharmacology, 29(9), 983-995. doi: 10.1177/0269881115587929

Wang, G. Y., Kydd, R., Wouldes, T. A., Jensen, M., & Russell, B. R. (2015). Changes in resting EEG following methadone treatment in opiate addicts. Clinical Neurophysiology, 126(5), 943-950. doi: 10.1016/j.clinph.2014.08.021

Jan, R. K., Lin, J. C., McLaren, D. G., Kirk, I. J., Kydd, R. R., & Russell, B. R. (2014). The effects of methylphenidate on cognitive control in active methamphetamine dependence using functional magnetic resonance imaging. Frontiers in Psychiatry, 5, 20. doi: 10.3389/fpsyt.2014.00020

Wang, G. Y., Wouldes, T. A., Kydd, R., Jensen, M., & Russell, B. R. (2014). Neuropsychological performance of methadone-maintained opiate users. Journal of Psychopharmacology, 28(8), 789-799. doi: 10.1177/0269881114538541

Miles, S. W., Sheridan, J., Russell, B., Kydd, R., Wheeler, A., Walters, C., … Tiihonen, J. (2013). Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: A randomized, double-blind, placebo-controlled trial. Addiction, 108(7), 1279-1286. doi: 10.1111/add.12109

Young, S. A., Thrimawithana, T. R., Antia, U., Fredatovich, J. D., Na, Y., Neale, P. T., … Russell, B. (2013). Pharmaceutical quality of "party pills" raises additional safety concerns in the use of illicit recreational drugs. New Zealand Medical Journal, 126(1376). Retrieved from http://www.nzma.org.nz/journal

Sun, Y., Evans, J., Russell, B., Kydd, R., & Connor, B. (2013). A benzodiazepine impairs the neurogenic and behavioural effects of fluoxetine in a rodent model of chronic stress. Neuropharmacology, 72, 20-28. doi: 10.1016/j.neuropharm.2013.04.021

Curley, L. E., Kydd, R. R., Kirk, I. J., & Russell, B. R. (2013). Differential responses to anticipation of reward after an acute dose of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) alone and in combination using functional magnetic resonance imaging (fMRI). Psychopharmacology, 229(4), 673-685. doi: 10.1007/s00213-013-3128-3

Wang, G. Y., Wouldes, T. A., & Russell, B. R. (2013). Methadone maintenance treatment and cognitive function: A systematic review. Current Drug Abuse Reviews, 6(3), 220-230. doi: 10.2174/18744737112059990020

Jan, R. K., Lin, J. C., Miles, S. W., Kydd, R. R., & Russell, B. R. (2012). Striatal volume increases in active methamphetamine-dependent individuals and correlation with cognitive performance. Brain Sciences, 2(4), 553-572. doi: 10.3390/brainsci2040553

McNabb, C. B., Russell, B. R., Caprioli, D., Nutt, D. J., Gibbons, S., & Dalley, J. W. (2012). Single chemical entity legal highs: Assessing the risk for long term harm. Current Drug Abuse Reviews, 5(4), 304-319. doi: 10.2174/1874473711205040005

Jan, R. K., Kydd, R. R., & Russell, B. R. (2012). Functional and structural brain changes associated with methamphetamine abuse. Brain Sciences, 2(4), 434-482. doi: 10.3390/brainsci2040434

Ram, S., Russell, B., Gubb, M., Taylor, R., Butler, C., Khan, I., & Shelling, A. (2012). General practitioner attitudes to direct-to-consumer genetic testing in New Zealand. New Zealand Medical Journal, 125(1364), 14-26. Retrieved from http://www.nzma.org.nz/journal

Lin, J. C., Jan, R. K., Kydd, R. R., & Russell, B. R. (2011). Subjective effects in humans following administration of party pill drugs BZP and TFMPP alone and in combination. Drug Testing & Analysis, 3(9), 582-585. doi: 10.1002/dta.285

Thornley, S., Russell, B., & Kydd, R. (2011). Carbohydrate reward and psychosis: An explanation for neuroleptic induced weight gain and path to improved mental health? Current Neuropharmacology, 9(2), 370-375. doi: 10.2174/157015911795596513

Lee, H., Kydd, R. R., Lim, V. K., Kirk, I. J., & Russell, B. R. (2011). Effects of trifluoromethylphenylpiperazine (TFMPP) on interhemispheric communication. Psychopharmacology, 213(4), 707-714. doi: 10.1007/s00213-010-2025-2

McIlwain, M. E., Harrison, J., Wheeler, A. J., & Russell, B. R. (2011). Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatric Disease & Treatment, 7(1), 135-149. doi: 10.2147/NDT.S12769

Lin, J. C., Jan, R. K., Lee, H., Jensen, M.-A., Kydd, R. R., & Russell, B. R. (2011). Determining the subjective and physiological effects of BZP combined with TFMPP in human males. Psychopharmacology, 214(3), 761-768. doi: 10.1007/s00213-010-2081-7

Jan, R. K., Lin, J. C., Lee, H., Sheridan, J. L., Kydd, R. R., Kirk, I. J., & Russell, B. R. (2010). Determining the subjective effects of TFMPP in human males. Psychopharmacology, 211(3), 347-353. doi: 10.1007/s00213-010-1911-y

Anita, U., Tingle, M. D., & Russell, B. R. (2010). Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. Journal of Forensic Sciences, 55(5), 1311-1318. doi: 10.1111/j.1556-4029.2010.01457.x

Antia, U., Lee, H. S., Kydd, R. R., Tingle, M. D., & Russell, B. R. (2009). Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Science International, 186(1-3), 63-67. doi: 10.1016/j.forsciint.2009.01.015

Anita, U., Tingle, M. D., & Russell, B. R. (2009). 'Party pill' drugs: BZP and TFMPP. New Zealand Medical Journal, 123, 1307, 55-68.

Murphy, M., Antia, U., Chang, H.-Y., Han, J. Y., Ibrahim, A., Tingle, M., & Russell, B. (2009). Party pills and drug-drug interactions. New Zealand Medical Journal, 122(1293), 16-25. Retrieved from https://www.nzma.org.nz/journal

Antia, U., Tingle, M. D., & Russell, B. R. (2009). In vivo interactions between BZP and TFMPP (party pill drugs). New Zealand Medical Journal, 122(1303), 29-38. Retrieved from https://www.nzma.org.nz/journal

Lin, J. C., Bangs, N., Lee, H., Kydd, R. R., & Russell, B. R. (2009). Determining the subjective and physiological effects of BZP on human females. Psychopharmacology, 207(3), 439-446. doi: 10.1007/s00213-009-1669-2

Antia, U., Tingle, M. D., & Russell, B. R. (2009). Metabolic interactions with piperazine-based 'party pill' drugs. Journal of Pharmacy & Pharmacology, 61(7), 877-882. doi: 10.1211/jpp/61.07.0006

Sheridan, J., Butler, R., Wilkins, C., & Russell, B. (2007). Legal piperazine-containing party pills: A new trend in substance misuse. Drug & Alcohol Review, 26(3), 335-343. doi: 10.1080/09595230701255791

Russell, B. R., & Laverty, R. (2001). The effect of (R)-HA966 or ACEA 1021 on dexfenfluramine or (S)-MDMA-induced changes in temperature, activity and neurotoxicity. Pharmacology Biochemistry & Behavior, 68(3), 565-574. doi: 10.1016/S0091-3057(01)00454-3

Russell, B. R., & Laverty, R. (2000). Correlation between 5-HT content and uptake site density following (S)-MDMA and dexfenfluramine-induced depletion, and with neuroprotection by the glycine site-specific NMDA antagonist ACEA 1021. Annals of the New York Academy of Sciences, 914, 208-214. doi: 10.1111/j.1749-6632.2000.tb05197.x

Zheng, Y., Russell, B., Schmierer, D., & Laverty, R. (1997). The effects of aminorex and related compounds on brain monoamines and metabolites in CBA mice. Journal of Pharmacy & Pharmacology, 49(1), 89-96. doi: 10.1111/j.2042-7158.1997.tb06758.x

Russell, B. R., Beresford, R. A., Schmierer, D. M., McNaughton, N., & Clark, C. R. (1995). Stimulus properties of some analogues of 4-methylaminorex. Pharmacology Biochemistry & Behavior, 51(2-3), 375-378. doi: 10.1016/0091-3057(94)00407-A

^ Top of page

Journal - Research Other

Wilkins, C., Sheridan, J., Adams, P., Russell, B., & Newcombe, D. (2013). Reply to Sumnall (2013): 'The New Zealand new psychoactive substances regime: A step in the right direction, but questions still remain'. Journal of Psychopharmacology, 27(11), 1078-1079. doi: 10.1177/0269881113503507a

Wilkins, C., Sheridan, J., Adams, P., Russell, B., Ram, S., & Newcombe, D. (2013). The new psychoactive substances regime in New Zealand: A different approach to regulation [Perspective]. Journal of Psychopharmacology, 27(7), 584-589. doi: 10.1177/0269881113491441

Sheridan, J., Atmore, B., & Russell, B. (2012). New Zealand to establish fit for purpose regulation for new psychoactive substances. Addiction, 107(11), 1901-1902. doi: 10.1111/j.1360-0443.2012.03809.x

Hardy, I., Alany, R., Russell, B., & Hardy, G. (2006). Antimicrobial effects of arginine and nitrogen oxides and their potential role in sepsis [Editorial]. Current Opinion in Clinical Nutrition & Metabolic Care, 9(3), 225-232. doi: 10.1097/01.mco.0000222104.23171.58

More publications...